AbbVie, a leading pharmaceutical company, has initiated a new USD 223 million expansion of its manufacturing facility in Singapore’s Tuas Biomedical Park. This investment aims to bolster AbbVie’s global manufacturing capacity for biologics, generating over 100 new jobs in the process.
The Singapore plant, renowned for its advanced small-molecule and biologics manufacturing capabilities, serves markets worldwide. This new investment will add 24,000 liters of biologics drug-substance capacity to AbbVie’s global manufacturing network and support current products as well as emerging immunology and oncology compounds within AbbVie’s pipeline.
Azita Saleki-Gerhardt, AbbVie’s Executive Vice President and Chief Operations Officer, highlighted the significance of this expansion in reinforcing global manufacturing capabilities and fulfilling patient commitments.
Over the past decade, AbbVie has invested over USD 740 million in its Singapore facility, marking a decade-long partnership with the Government of Singapore. Once operational, the expanded site will employ over 500 professionals in various roles.
Construction is slated to commence in 2024, with operations projected to start in 2026. AbbVie’s Singapore manufacturing plant is part of its broader Operations team, comprising 14,000 employees across numerous sites globally.
(Source: AbbVie)
